Best IVF Protocol for Low Ovarian Reserve: The Stimulation Protocols Compared

Most patients who come to us with low ovarian reserve are already holding a protocol someone else chose, and the question they actually want answered is whether it is the right one for them.

There is no single best IVF protocol for low ovarian reserve. In the largest analysis of US cycles, the antagonist and microdose Lupron flare protocols produced cumulative live birth rates of 14.2% and 13.6% in poor responders, and the current ESHRE guideline treats several other approaches as equally recommended. What changes your odds is matching the protocol to your AMH, your antral follicle count and the way your ovaries responded last time.

That is harder to act on than a ranking would be, and it is why so many patients end up climbing the dose instead. Spend an evening in the low reserve forums and you will read about 450 and 600 IU cycles prescribed after a disappointing retrieval. The guideline puts the ceiling at 300, and says plainly that going above it is not recommended for predicted low responders.

What follows is every stimulation protocol used for diminished ovarian reserve, one at a time: Mini IVF, natural and modified natural cycle IVF, dual stimulation, the antagonist protocol, estrogen-primed luteal antagonist and microdose Lupron flare, with how each one works, who it suits and what you give up. Then how the right protocol gets chosen from your own numbers, what the gonadotropin dose can and cannot do, and what the evidence actually says about the add-ons sold alongside IVF treatment.

The Best IVF Protocols for Low Ovarian Reserve, Compared Protocol by Protocol

Every option above is a form of ovarian stimulation, and the order is deliberate: the approaches designed around a small follicle pool come first, and the conventional protocols follow.

Between the two conventional ones, the numbers are close. In a propensity-matched analysis of US cycles reported to SART CORS between 2014 and 2019, patients with a predicted poor response (AMH below 0.5) on their first cycle had a cumulative live birth rate of 14.2% on the antagonist protocol (95% CI 13.6 to 14.8) versus 13.6% on flare (95% CI 12.4 to 14.8). Those intervals overlap. So between antagonist and flare, the tie-breakers are cancellation risk, cycle flexibility, injection burden and how your ovaries behaved last time.

Mini IVF

Mini IVF uses an oral medication, clomiphene citrate or letrozole, on roughly days 1 to 5, then low-dose injectable gonadotropins from around day 6 if they are needed. Most patients take one pill a day and only a handful of injections across the whole cycle. Stimulation goes ahead once enough antral follicles are visible at the baseline scan.

For a low responder, the evidence puts this approach on a level with conventional stimulation. The ESHRE guideline on ovarian stimulation states that clomiphene citrate alone, clomiphene combined with gonadotropins, and gonadotropin stimulation alone are probably equally recommended for predicted low responders.

What you gain:

• Lower medication costs, often by a wide margin
• Far fewer injections
• Three to four monitoring visits instead of six to eight
• Much less hormone exposure
• Essentially no risk of ovarian hyperstimulation syndrome

Why it fits low ovarian reserve in particular: when the follicle pool is small, a high-dose protocol will not recruit follicles that are not there. A gentler cycle targets the eggs available instead of pushing the ovaries for a return they cannot give.

Lower cost per cycle also makes repeating realistic, which is how a small yield per retrieval is usually worked with. What Mini IVF costs comes down to medication and any add-ons you choose. One note on the oral agent itself: adding letrozole to gonadotropins is probably not recommended for predicted low responders, while clomiphene-based stimulation carries the equal recommendation above.

Natural and Modified Natural Cycle IVF

A true natural cycle uses no stimulation at all and retrieves the single egg your body selected that month. A modified natural cycle adds a low dose of gonadotropin and usually a GnRH antagonist, which guards against premature ovulation losing the egg before retrieval.

The guideline position comes in two halves, and you need both. The modified natural cycle is probably not routinely recommended over conventional stimulation for low responders. The same guideline then adds that low responders are a varied group, and that in women with diminished ovarian reserve at the severe end, clinicians could reasonably choose a modified natural cycle.

The trade-off is cancellation. A 2007 review of stimulation protocols for diminished ovarian reserve reported cancellation rates ranging from 14.3% to 62.5% across the studies it looked at.

Clinicians still use it for a straightforward reason. In women with diminished ovarian reserve who produce one or two follicles under stimulation anyway, the stimulation may be buying cost and side effects rather than eggs, and a single egg retrieval on an unstimulated cycle costs far less.

Dual Stimulation (DuoStim)

Dual stimulation IVF is a scheduling strategy rather than an alternative stimulation protocol. It is layered on one: two stimulations and two egg retrieval procedures inside a single menstrual cycle, one in the follicular phase and one in the luteal phase.

The guideline is unusually supportive here. Double stimulation can be used with the intention to accumulate oocytes or embryos when a fresh transfer is not planned. Luteal start stimulation could be used when a fresh transfer is not intended and there is no possibility of natural conception.

It suits patients whose yield per cycle is too small for one retrieval to produce a transferable embryo, and who are working against time. Two retrievals a few weeks apart instead of a few months apart.

The constraint: it requires a freeze-all approach, so there is no fresh embryo transfer that cycle. The transfer happens later, once the embryos are banked.

Antagonist Protocol (Short Protocol)

Gonadotropin stimulation starts on day 2 or 3 of your menstrual cycle, and a GnRH antagonist, either ganirelix or cetrorelix, is added partway through to block a premature LH surge. GnRH antagonists block the receptor directly, so they work within hours rather than needing weeks of prior suppression, and that is what prevents early ovulation before retrieval.

It is the usual starting point for a reason. The 2025 ESHRE guideline recommends the antagonist protocol over agonist protocols in the general IVF population, on grounds of comparable efficacy and better safety. For predicted poor responders specifically, the 2019 ESHRE guideline concluded that antagonists and agonists are equally recommended, and the 2025 update did not overturn that.

For low reserve, the practical advantages are: no long downregulation phase, fewer injections overall, a shorter cycle, and the chance to see your baseline antral follicle count and decide whether to start at all before committing to expensive gonadotropins.

On birth control pills beforehand, which comes up constantly: combined oral contraceptive pill pretreatment is not recommended in the antagonist protocol with FSH-alone stimulation, because of reduced efficacy. Where the pill is used simply to schedule a cycle ahead of a fresh transfer, the guideline notes that a minimum washout period of 5 days may be applied. That is a specific thing you can ask your clinic about.

The antagonist can be started on a fixed day or once the lead follicle reaches a set size, which clinics call a flexible protocol. Worth asking which one you are on.

The trade-off is less control over follicle synchrony than a primed cycle, which matters if your follicles have grown at different rates before. That is what the next protocol addresses. One related option you may be offered by name: antagonist pretreatment in a delayed-start gonadotropin protocol is probably not recommended.

Estrogen-Primed Luteal Antagonist Protocol

Estradiol, usually as an oral tablet or an estrogen patch, is given in the luteal phase of the preceding cycle. It suppresses the FSH rise that would otherwise recruit a lead follicle in the early stages, so the cohort enters stimulation at a similar size and the follicles develop together. Stimulation then runs as a standard antagonist cycle.

Priming synchronises, it does not recruit. It will not add follicles to your pool. It is there to support follicle development, not to create it: by evening out follicle growth at the start, more of the follicles you already have reach maturity together. Many patients expect their antral follicle count to rise on a primed cycle and are disappointed when it does not.

The difference between even and uneven follicular development is the whole rationale. Where follicular growth is staggered, the lead follicle is ready while the rest are still small, and the cycle gets triggered on a cohort that was never going to mature together.

It suits anyone whose monitoring scans have shown one follicle racing ahead while the rest stalled, and anyone whose last cycle produced a high proportion of immature eggs rather than mature eggs. Where follicle development has been uneven before, this is the protocol that addresses it.

The trade-off: the same suppression that lines the cohort up can blunt the response in some patients. The ESHRE guideline carries no recommendation specific to estradiol pretreatment in low responders, so this remains a clinical judgement call rather than a settled one.

Microdose Lupron Flare Protocol

A very low dose of leuprolide acetate in the early follicular phase first triggers a surge, the flare, of your own FSH and LH before the pituitary downregulates. The aim is extra follicular recruitment, using your body’s own gonadotropins on top of the injected ones.

It is aimed at poor responders in IVF who have already had a documented poor ovarian response on a conventional protocol. It is rarely the first protocol offered to someone who has never stimulated.

On the evidence, it produces cumulative live birth rates comparable to the antagonist protocol in the registry analysis above. Older reviews reported gains in peak estradiol, follicle recruitment and mature oocyte numbers on a flare protocol, while concluding that larger studies were needed.

The trade-off is a real risk of cycle cancellation for poor response. Some patients get their best maturity and blastocyst rates here with fewer eggs than on antagonist, and others lose the cycle entirely. Responses vary enough between patients that this cannot be predicted in advance.

A note on the long agonist protocol, since it is sometimes offered. It uses weeks of downregulation before stimulation begins. Where a GnRH agonist is used, the guideline states that the long protocol is recommended over the short or ultrashort agonist protocol. In low reserve, the clinical concern is different: prolonged suppression can leave too little response to recover, which is why it is usually set aside here.

Choosing Between Them: AMH, Antral Follicle Count, Age and Prior Cycle Response

These four inputs are what a reproductive endocrinologist is reading when choosing between the protocols above. If you know your own numbers, you can have a much better conversation about them.

The Ovarian Reserve Numbers: AMH, Antral Follicle Count and Day 3 FSH

The ESHRE guideline recommends using either antral follicle count or AMH to predict high and low response. It publishes no single numeric threshold, which is why different clinics quote you different cutoffs.

What each one tells you:

• AMH reflects the size of the remaining pool
• The count of antral follicles on the baseline scan shows how many are available this cycle
• Follicle stimulating hormone, measured on day 3 and reported as your day 3 FSH levels, rises as the ovaries become harder to stimulate

Together they estimate ovarian sensitivity, meaning how much response a given dose is likely to produce. A falling result is the usual reason people start reading about how to increase AMH levels, though the number describes the pool rather than controlling it. Diminished ovarian reserve is the label those numbers earn, and a full medical history sits alongside them, since surgery, endometriosis, chemotherapy and a family history of early menopause all bear on the reading.

Two formal definitions sit behind the label:

The Bologna criteria (ESHRE, 2011) require at least two of three features:

• Advanced maternal age, 40 or over, or another risk factor for poor response
• A previous poor response, meaning three or fewer oocytes on a conventional protocol
• An abnormal ovarian reserve test: antral follicle count below 5 to 7, or AMH below 0.5 to 1.1 ng/mL

Two episodes of poor response after maximal stimulation are enough on their own, even without advanced age or an abnormal test.

The POSEIDON stratification (2016) splits the same population into four groups:

The practical distinction is worth understanding. Normal markers with a poor response anyway is a protocol or dosing problem worth solving. Markers that were low from the start is a different situation, working against the size of the follicle pool. Grouping both together as low ovarian reserve hides that difference.

POSEIDON also redefined success as retrieving the number of eggs needed to obtain at least one euploid blastocyst, which changes what a good cycle looks like for you.

Prior Cycle Response: Eggs Retrieved, Maturity and Follicle Synchrony

A previous stimulation is the most informative input available, and no blood test replaces it. Your previous cycles show how the ovaries respond in practice, which is the part of your treatment history that actually drives the next protocol. Many readers also carry an unexplained infertility label alongside the low reserve numbers, and the stimulation record speaks to the protocol question in a way that label does not.

Ask your clinic for the full monitoring record, not the summary letter. You are entitled to it, and clinics release it on request. What to look at:

• Eggs retrieved at egg retrieval against the count from the baseline ultrasound. A large gap points at timing, trigger or synchrony rather than reserve.
• Maturity rate, meaning mature eggs as a share of eggs retrieved. A low rate is the pattern most often linked to over-suppression, or to triggering on an uneven cohort.
• Follicle synchrony on the monitoring scans. One follicle racing ahead is the problem estrogen priming addresses.
• Fertilization rate, including whether intracytoplasmic sperm injection was used, and how many embryos survived blastocyst culture to day 5. Slow embryo development and fewer embryos than the egg count suggested speak to egg quality rather than the protocol, which is a different conversation, and sometimes where donor eggs get raised.
• Whether the cycle was cancelled, and at what point.

Where a first cycle was cancelled, the evidence points somewhere specific. A 2024 analysis of 13,135 patients in the SART CORS database whose first cycle was cancelled during stimulation found that changing protocol for cycle two carried 14% lower odds of a second cancellation (adjusted OR 0.86, 95% CI 0.76 to 0.97) and 17% higher odds of live birth after a fresh transfer (adjusted OR 1.17, 95% CI 1.00 to 1.37). The lower bound on that second interval sits on 1.00, so treat the live birth figure as a signal worth acting on rather than a settled result.

The same analysis reports switch-specific odds ratios in poor ovarian responders:

• Antagonist protocol to agonist suppression: OR 1.36
• Agonist suppression to antagonist protocol: OR 1.73

Both directions outperformed repeating the same protocol. The evidence supports changing, and does not crown one destination. The authors note a limitation worth knowing: SART tracks only three stimulation protocols and holds no data on the more contemporary ones, so these findings say nothing about Mini IVF, dual stimulation or primed variants.

Questions worth asking at the follow-up: what was my peak estradiol, how many follicles were over 14 mm at trigger, why was this trigger chosen, and what specifically would you change next time.

Gonadotropin Dose: the 150 to 300 IU Range and the Ceiling Above It

A gonadotropin dose higher than 300 IU is not recommended for predicted low responders. The honest second half: it is unclear whether a dose higher than 150 IU is better than 150 IU at all.

The guideline treats 150 to 225 IU as conventional dosing, and states there are limited indications to go outside that range. It also notes a lack of evidence for the value of dose adjustments made during stimulation, which is why the starting dose is the part worth discussing.

On drug choice, since patients are often told a specific brand suits low reserve better:

• Recombinant FSH and human menopausal gonadotropin are equally recommended
• Adding recombinant LH to recombinant FSH is probably equally recommended to recombinant FSH alone for low responders

Escalating the dose is the most common response to a disappointing cycle, and the one with the least evidence behind it. How the ovaries respond is set more by the size of the pool than by the number on the vial.

What the Add-Ons Do and Do Not Change: Growth Hormone, DHEA, Testosterone and Supplements

These are the interventions most heavily promoted to patients with low ovarian reserve, most are paid out of pocket, and the current guideline recommends against most of them. Every one is sold on the same promise, to improve ovarian response or to enhance ovarian response before a cycle.

A few specifics worth having:

DHEA carries the firmest position of the group. It also hardened over time: the 2020 edition of the guideline said “probably not recommended”, and the current edition states “not recommended”, on the back of newer evidence.

Growth hormone has a longer story. Earlier small studies reported more oocytes, while randomised trials and a Cochrane meta-analysis did not confirm a benefit in follicle or oocyte numbers. It is also expensive, and rarely included in infertility insurance coverage.

Testosterone and DHEA became popular for a reason that makes biological sense: androgens act on follicles in the early stages of recruitment, and early uncontrolled studies were encouraging. Controlled trials did not show a benefit in ovarian response.

Ovarian PRP, sometimes sold as ovarian rejuvenation, is offered by some clinics for diminished ovarian reserve. No professional body recommends it, and the published work so far is small studies and proposed frameworks rather than an established position.

The absence of a recommendation is not evidence of harm, and none of this is a reason to stop something you are already taking. It is a reason to ask your physician what the evidence is in your specific case.

Get A Stimulation Plan Built From Your Own Numbers

No single protocol wins for low ovarian reserve, and the current guideline treats several of them as equally recommended. Which one fits you is read off your AMH, your antral follicle count, your age and how your ovaries responded in previous cycles rather than off a protocol’s reputation. More medication does not produce more eggs: above 300 IU nothing improves, priming synchronises the follicles you already have rather than adding to them, and most of the add-ons sold alongside a cycle are not supported by the guideline. After a cancelled cycle, the data point away from repeating the same protocol unchanged.

What a consultation adds is the specialist reading of those numbers and the plan that follows from it. The right protocol is only as good as the interpretation behind it, and nobody can choose one from a forum post or a blog, including this one.

Dr. Eliran Mor and team are board-certified in reproductive endocrinology and infertility, our IVF success rates run about twice the national cumulative average, and we have helped build more than 3,000 families over 20+ years.

Wherever you are in your fertility journey, request an appointment with our fertility specialists in Los Angeles. We can’t promise you a baby, but we can promise you the most advanced, personalized care in reproductive medicine to maximize your chance of one, and a protocol you can see the reasoning behind.